Antimicrobial Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections

Methicillin-resistant Staphylococcus aureus (MRSA) remains a leading cause of healthcare- and community-associated infections worldwide, posing significant challenges due to its resistance to β-lactam antibiotics. Current treatment strategies centre on glycopeptides such as vancomycin, oxazolidinones such as linezolid, lipopeptides such as daptomycin and newer agents including ceftaroline and dalbavancin. Clinicians must balance antimicrobial efficacy against potential toxicity, emerging resistance and pharmacokinetic/pharmacodynamic considerations. Combination regimens (for example vancomycin with rifampin or minocycline with rifampin) and adjunctive modalities (such as low-frequency ultrasound) are under evaluation in complex skin, soft tissue and pulmonary infections. Stewardship measures and dose optimisation remain critical to prolong the utility of existing agents, while novel antibiotics and immunomodulatory approaches are in development to address refractory and invasive disease.

Research from Nature Portfolio

A pivotal study has demonstrated that linezolid possesses immunomodulatory activity beyond its antimicrobial action. In models of ventilator-associated pneumonia where neutrophil function is impaired by complement fragment C5a, co-incubation with linezolid restored key neutrophil functions including bacterial killing, phagocytosis and chemotactic response. This work reveals that linezolid can protect dysfunctional innate immune cells and suggests a dual role in both direct bacterial clearance and modulation of host defences.

Antimicrobial Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections publication trend

The graph below shows the total number of articles in antimicrobial treatment strategies for methicillin-resistant staphylococcus aureus infections across all publications each year (not limited to Nature Index journals).

Technical terms

Methicillin-resistant Staphylococcus aureus (MRSA): A strain of S. aureus harbouring the mecA gene, conferring resistance to all β-lactam antibiotics.

Oxazolidinone: A class of synthetic antibiotics (for example linezolid, tedizolid) that inhibit bacterial protein synthesis by binding the 50S ribosomal subunit.

Glycopeptide: A class of antibiotics (for example vancomycin) that inhibit cell wall synthesis by binding to D-alanine residues in peptidoglycan precursors.

Network meta-analysis: A statistical method allowing comparison of multiple treatments by integrating direct and indirect evidence from clinical trials.

Low-frequency ultrasound (LFU): A therapeutic ultrasound modality used to enhance antibiotic penetration and disrupt bacterial biofilms in infected tissues.

References

1. The treatment of resistant staphylococcal infections. F1000Research (2020).
2. Contrasting effects of linezolid on healthy and dysfunctional human neutrophils: reducing C5a-induced injury. Scientific Reports (2020).
3. Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis. Antibiotics (2024).
4. Effects of low-frequency ultrasound combined with anti-MRSA agents on the mouse model of pulmonary infection. Microbiology Spectrum (2024).
5. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrobial Resistance & Infection Control (2019).